FDA delays ruling on AstraZeneca drug after negative adcomm vote - Fierce Biotech

FDA delays ruling on AstraZeneca drug after negative adcomm vote Fierce Biotech US regulator delays decision on AstraZeneca cancer drug Financial Times Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm Fierce Pharma Pharmalittle: We're reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more statnews.com AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data The Independent